Gordon Saxty

This inventor holds 42 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 18 EPO patents, primarily in Bicyclic Heterocycles. Top assignees: Astex Therapeutics Limited, Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gordon Saxty. Retrieved from https://idiyas.com/inventor/gordon-saxty

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 4)

% Patents Active = 83.3

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 18 (Patent Applications = 14)

Average Co-Inventor Count = 8.7

ph-index = 13

Forward Citations = 414(Granted Patents)

Location History:

Cambridge, GA (2014)
Cambridge, GB (2011 - 2019)
Zagreb, HR (2016 - 2023)

Company Filing History:

38 out of 126

Astex Therapeutics Limited

patents

6 out of 268

Cancer Research Technology Limited

patents

6 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

patents

4. 1 out of 12

Centessa Pharmaceuticals (UK) Limited

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Bicyclic Heterocycles

FGFR Inhibitors

Pyrazolyl Compounds

Pyrrolopyrimidine

Quinoxalines

Pteridines

Protein Kinase Modulators

Macrolide Compounds

Tyrosine Kinase Inhibitors

Cancer Treatment

Therapeutic Uses

Pharmacophore Compounds

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679804 - 2-(3-ethynylbenzyl)-substituted heterocycle derivatives and related uses (2026-07-14),

2. 11643410 - Bicyclic heterocycle compounds and their uses in therapy (2023-05-09),

3. 11512096 - Seco macrolide compounds (2022-11-29),

4. 11225476 - Bicyclic heterocycle compounds and their uses in therapy (2022-01-18),

5. 11136325 - Pyrrolopyrimidine and pyrrolopyridine derivatives (2021-10-05),

6. 10919910 - Seco macrolide compounds (2021-02-16),

7. 10618895 - Bicyclic heterocycle compounds and their uses in therapy (2020-04-14),

8. 10519137 - Pyrazolyl quinoxaline kinase inhibitors (2019-12-31),

9. 10272087 - Pteridines as FGFR inhibitors (2019-04-30),

10. 10052320 - Substituted quinoxalines as FGFR kinase inhibitors (2018-08-21),

11. 10045982 - Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors (2018-08-14),

12. 10039759 - Quinolines as FGFR kinase modulators (2018-08-07),

13. 9980973 - Bicyclic heterocycle compounds and their uses in therapy (2018-05-29),

14. 9856236 - Substituted quinoxalines as FGFR kinase inhibitors (2018-01-02),

15. 9850228 - Pyrazolyl quinoxaline kinase inhibitors (2017-12-26),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I regret to inform you that I can only provide information related to these specific topics.

Profile summary based on public USPTO records.